MKI67 and invasive breast carcinoma: In this single-center, retrospective cohort of 79 patients with invasive breast carcinoma, paired immunohistochemical assessment of ER, PR, HER2, and Ki-67 on diagnostic core biopsies and surgical specimens confirmed a high overall level of concordance, but also documented a non-negligible subset of clinically relevant reclassifications.